Clinical Trial

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

Study acronym: REPOSE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-03-13; most recent amendment 2026-02-23.
Status change: Not Yet Recruiting → Recruiting 2025-04-16
Trial Details
NCT Number NCT06315010
Lead Sponsor MedSIR
Collaborators: Medical University of Vienna
Conditions NSCLC, Brain Metastases, ROS1 Gene Rearrangement
Enrollment 20 participants
Start Date 2025-06-27
Primary Completion 2027-03 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-25